Clinical Trials

ED-initiated Buprenorphine at Penn Presbyterian Medical Center

Emergency physicians at Penn Presbyterian ED are leading a NIDA funded national study, ED-INNOVATION,  to address the optimal formulation of buprenorphine for initiation of MOUD.   CAM2038 is a slow release injection of buprenorphine that lasts for 7 days. The study team, led by Dr. Jeanmarie Perrone and including colleagues Dr. David Jang, Dr. Anish Agarwal, Dr. Zachary Meisel and Dr. Sean Foster will assess whether the injection can be a more successful bridge than usual care with sublingual buprenorphine to follow up treatment at 7 days .

Pharmacogenetics of Agonist Therapy for Opioid Use Disorder in African Americans

Wade H. Berrettini MD, PhD is leading a multi-site study involving African Americans that are dependent on opioids. This clinical study will examine opioid receptor variants as predictors of therapeutic response to buprenorphine and methadone amongst this population. This project is an attempt to confirm that observation in a treatment-as-usual setting.

Remote Observed Dosing to Improve Suboxone Compliance in Clinical Practice

This Remote Observed Dosing to Improve Suboxone Compliance in Clinical Practice (RODS) study is assessing the preliminary efficacy of using remote compliance monitoring in buprenorphine (Suboxone) treatment for Opioid Use Disorder (OUD). All participants will receive a smartphone that they can keep at the completion of the study and will also receive Suboxone and weekly Medication Management (MM) counseling for 12 weeks. Participants will be assessed at weekly visits for a total of 15 weeks. Subjects will be paid for their time.

Providers  may refer patients to the study by sending a message in PennChart to Megan Ivey [IveyMe], or calling Matt Taylor or Megan Ivey. Principal Investigator: Kyle Kampman, MD Project Manager: Megan Ivey (meganl@pennmedicine.upenn.edu, 215-746-7712) Research Coordinator: Matt Taylor (matthew.taylor@pennmedicine.upenn.edu, 215-746-0467)